Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,496.48 -17.89 -0.11%
S&P 500 1,878.63 -0.92 -0.05%
NASDAQ 4,142.10 -19.36 -0.47%
Ticker Volume Price Price Delta
STOXX 50 3,188.84 -10.85 -0.34%
FTSE 100 6,673.59 -8.17 -0.12%
DAX 9,581.14 -18.95 -0.20%
Ticker Volume Price Price Delta
NIKKEI 14,546.27 157.50 1.09%
TOPIX 1,173.81 11.31 0.97%
HANG SENG 22,509.64 -221.04 -0.97%

Synageva BioPharma™ to Present at the 31st Annual J.P. Morgan Healthcare Conference



  Synageva BioPharma™ to Present at the 31st Annual J.P. Morgan Healthcare
  Conference

JPMorgan Healthcare Conference 2013

Business Wire

LEXINGTON, Mass. -- December 19, 2012

Synageva BioPharma Corp. (“Synageva”) (NASDAQ:GEVA), a clinical stage
biopharmaceutical company developing therapeutic products for rare disorders,
announced today its presentation at the upcoming J.P. Morgan Healthcare
conference being held in San Francisco, CA.

Sanj K. Patel, President and Chief Executive Officer of Synageva, will present
on Wednesday, January 9, 2013, at 10:30 AM PDT (1:30 PM EST). The presentation
will be webcast live and may be accessed from the “Webcasts & Presentations”
section of the Investor Relations tab on the home page of Synageva’s website
at www.synageva.com.

About Synageva’s Lead Program

Sebelipase alfa is a recombinant form of the human LAL enzyme under
development by Synageva as an enzyme replacement therapy for LAL Deficiency, a
lysosomal storage disorder (LSD). Synageva is currently evaluating sebelipase
alfa in global clinical trials and sebelipase alfa has been granted orphan
designations by the U.S. Food and Drug Administration (FDA), the European
Medicines Agency, and the Japanese Ministry of Health, Labour and Welfare.
Additionally, sebelipase alfa received “fast track” designation by the FDA.

About LAL Deficiency

LAL Deficiency is a rare, autosomal recessive LSD caused by a marked decrease
in LAL enzyme activity. Late onset LAL Deficiency, sometimes called
Cholesteryl Ester Storage Disease (CESD), affects both children and adults. In
these patients, the buildup of fatty material in the liver, spleen and blood
vessel walls leads to complications resulting in significant morbidity and
mortality. Early onset LAL Deficiency, sometimes called Wolman disease,
affects infants and is characterized by severe malabsorption, growth failure,
and liver failure and is usually fatal within the first six months of life.

About Synageva BioPharma Corp.

Synageva is a clinical stage biopharmaceutical company focused on the
discovery, development, and anticipated commercialization of therapeutic
products for patients with life-threatening rare diseases and unmet medical
need. Synageva has several protein therapeutics in its drug development
pipeline. The company has assembled a team with a proven record of bringing
therapies to patients with rare diseases.

Further information regarding Synageva BioPharma Corp. is available at
www.synageva.com.

Forward-Looking Statements

This news release contains “forward-looking statements” under the provisions
of the Private Securities Litigation Reform Act of 1995. Such statements can
be identified by introductory words such as “expects,” “plans,” “intends,”
“believes,” “will,” “estimates,” “forecasts,” “projects,” or words of similar
meaning and by the fact that they do not relate strictly to historical or
current facts. Many factors may cause actual results to differ materially from
forward-looking statements, including inaccurate assumptions and a broad
variety of risks and uncertainties, some of which are known, including those
identified under the heading “Risk Factors” in the Company’s Quarterly Report
on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on
November 6, 2012, and other filings Synageva periodically makes with the SEC
and others of which are not. Synageva cannot be sure when or if it will be
permitted by regulatory agencies to undertake additional clinical trials or to
commence any particular phase of clinical trials or how quickly patient
enrollment in clinical trials will occur. In addition, early clinical results
are not necessarily predictive of results that may be achieved from subsequent
clinical trials. Because of this, statements regarding the expected timing of
clinical trials or ultimate regulatory approval cannot be regarded as actual
predictions of when Synageva will obtain regulatory approval for any phase of
clinical trials or when it will obtain ultimate regulatory approval by a
particular regulatory agency or when any of its drug product candidates might
be commercialized. Synageva’s future financial results may differ from those
currently anticipated due to a number of factors, including unanticipated
costs in its research and development programs, fluctuations in royalty
revenues and unplanned costs associated with maintaining and enforcing patents
and other patent-related costs. No forward-looking statement is a guarantee of
future results or events, and investors should avoid placing undue reliance on
such statements. Synageva undertakes no obligation to update any
forward-looking statements, whether as a result of new information, future
events or otherwise.

“Dedicated to Rare Diseases®” is a registered trademark and “Synageva
BioPharma™” is a trademark of Synageva BioPharma Corp.

Contact:

For Synageva:
Matthew Osborne, 781-357-9947
matthew.osborne@synageva.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement